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From the ‡Instituto de Salud Carlos III, Centro Nacional de Microbiología, 28220 Majadahonda (Madrid), Spain and the §Unité
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Background: Individuals with nonfunctional transporter associated with antigen processing (TAP) present HLA class I
ligands generated by TAP-independent processing pathways.
Results: Different subsets of metalloproteinases generate two vaccinia-derived TAP-independent epitopes.
Conclusion: Various proteolytic systems contribute to the antiviral cellular immune response, thereby facilitating
immunosurveillance.
Significance:Thismay explainwhyTAP-deficient individuals live normal life spanswithout any increased susceptibility to viral
infections.
The transporter associated with antigen processing (TAP)
translocates the viral proteolytic peptides generated by the pro-
teasome and other proteases in the cytosol to the endoplasmic
reticulum lumen. There, they complex with nascent human leu-
kocyte antigen (HLA) class I molecules, which are subsequently
recognized by the CD8 lymphocyte cellular response. How-
ever, individuals with nonfunctional TAP complexes or tumor
or infected cells with blocked TAPmolecules are able to present
HLA class I ligands generated by TAP-independent processing
pathways.Herein, using aTAP-independent polyclonal vaccinia
virus-polyspecific CD8 T cell line, two conserved vaccinia-de-
rived TAP-independent HLA-B*0702 epitopes were identified.
The presentation of these epitopes in normal cells occurs via
complex antigen-processing pathways involving the protea-
some and/or different subsets of metalloproteinases (amino-,
carboxy-, and endoproteases), which were blocked in infected
cells with specific chemical inhibitors. These data support the
hypothesis that the abundant cellular proteolytic systems con-
tribute to the supply of peptides recognized by the antiviral cel-
lular immune response, thereby facilitating immunosurveil-
lance. These data may explain why TAP-deficient individuals
live normal life spans without any increased susceptibility to
viral infections.
Newly synthesized viral proteins are recognized constantly
by CD8 lymphocytes as short peptides bound to human leu-
kocyte antigen (HLA) class I molecules at the cell surface of
infected cells (1). Proteolysis by the proteasome and other cyto-
solic proteases generates most of the peptides presented by
HLA class I molecules. These peptides are transported into the
endoplasmic reticulum (ER)2 by the transporter associatedwith
antigen processing (TAP), and subsequent N terminal trim-
ming by the metallo-aminoproteases ERAP1 and 2 is often
required (2, 3). Viral peptides assembled with newly synthe-
sized 2-microglobulin and HLA class I heavy chain generate
stable peptide-HLA complexes that are exported to the cell
membrane (reviewed in Ref. 4).
Mutations in the TAP genes that generate nonfunctional
TAP complexes have been described in both humans (5) and
mice (6). This HLA class I deficiency implies a reduced func-
tional CD8 population but does not correlate with any
increased susceptibility to viral infections or neoplasms. Thus,
TAP-deficient patients live normal life spanswith only a limited
susceptibility to chronic respiratory bacterial infections. There-
fore, their immune systems must be reasonably efficient, and
antibodies, NK cells, CD8 T cells, and the reduced cytolytic
CD8  T subpopulation that is specific for TAP-indepen-
dent antigens may all contribute to immune defenses that pro-
tect against severe viral infections in these individuals. Some
viruses block TAP expression or function to prevent cellular
immune responses from identifying infected cells (reviewed in
Ref. 7). Therefore, TAP-independent pathwaysmust be impor-
tant for killing cells infected with these viruses. TAP-indepen-
dent pathways of antigen presentation of various pathogenic
epitopes by MHC class I molecules have previously been
reported (reviewed in Refs. 7–9).* This work was supported by grants provided by Foundación para la Inves-
tigación y Prevención del SIDA en España and Ministerio de Ciencia e
Innovación.
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Cross-protective vaccination with orthopoxviruses, first
with an empirically developed vaccine against cowpox virus
and later through themassiveworldwide administration of vac-
cinia virus (VACV), achieved the eradication of smallpox, a
pandemic disease caused by variolamajor virus (10). The role of
cellular responses in this cross-protection is well documented
(11, 12). The cowpox protein CPXV12 inhibits peptide translo-
cation by TAP, thereby interfering with MHC class I-peptide
complex formation (13). Thus, the identification of TAP-inde-
pendent epitopes conserved among orthopoxviruses could be
relevant to the study of the mechanisms of early empirical vac-
cination against smallpox disease performed with cowpox
virus. In this study, using a TAP-independent polyclonal vac-
cinia virus-polyspecific CD8 T cell line, we identified two
VACV-derived TAP-independent epitopes that are conserved
among the Orthopoxviridae family, including cowpox virus.
EXPERIMENTAL PROCEDURES
Mice—H-2 class I double knock-out HLA-B*0702 transgenic
mice (14) were bred in our animal facilities in strict accordance
with the recommendations in theGuide for the Care andUse of
Laboratory Animals of the Spanish “ComisiónNacional de Bio-
seguridad” of the “Ministerio de Medio Ambiente y Medio
Rural y Marino” (accreditation number 28079–34A). The pro-
tocol was approved by the Committee on the Ethics of Animal
Experiments of the Institute of Health “Carlos III” (Permit
Number: PI-283). All surgery was performed under sodium
pentobarbital anesthesia, and all efforts weremade tominimize
suffering.
Cell Lines—The mouse cell lines RMA (TAP-positive) and
RMA-S (TAP-negative) stably expressing HLA-B*0702 12
domains plus the mouse H-2Db 3 transmembrane and cyto-
plasmic domains have been previously described (14). All cell
lines were cultured in RPMI 1640 medium supplemented with
10% fetal bovine serum and 5 M -mercaptoethanol.
Synthetic Peptides—Peptides were synthesized in a peptide
synthesizer (model 433A; Applied Biosystems, Foster City, CA)
and purified by reverse-phase HPLC. The correct molecular
mass of the peptides was established by MALDI-TOF MS, and
their correct composition was verified by quadrupole ion trap
micro-HPLC.
Inhibitors—Brefeldin A (BFA) and all protease inhibitors
were purchased from Sigma, with the exception of leupeptin
(Amersham Biosciences), pepstatin (Roche Applied Science),
benzyloxycarbonyl-VAD-fluoromethyl ketone (Enzyme Sys-
tem Products, CA), and lactacystin (Dr. E. J. Corey, Harvard
University). The specificity and activity of inhibitors used in
this study are summarized in Table 1. As a control for the activ-
ity of protease inhibitors that do not block antigen presenta-
tion, RMA-HLA-A*0201 cells (1  108) were disrupted by son-
ication for 15min at 4 °C and centrifuged as reported previously
(15). A supernatant aliquot corresponding to 1  107 cells was
directly frozen (nondegraded control). Equivalent aliquots
were incubated in the presence of individual inhibitors at 200
M, and digestion by cellular proteases was allowed for 5 days at
37 °C in PBS. Inhibitors were renewed daily. A sample incu-
bated without inhibitors was taken as the degraded control.
After SDS-PAGE separation and Coomassie Blue staining of
these samples, the overall protein content of each lane was
quantitated by densitometry with the TINA 2.09e program
(Isopenmessgeräte, GmbH, Germany). Percent inhibition of
protein degradation caused by each inhibitor was calculated as
follows: 100  (sample with inhibitor  degraded)/(nonde-
graded  degraded).
Ligand Prediction—The on-line program SYFPEITHI was
used to predict HLA-B*0702-specific ligands of VACV as
described previously (16).
Ex Vivo Intracellular Cytokine Staining (ICS)—Intracellular
cytokine staining assays were performed as described previ-
ously (17). Spleen cells were obtained fromHLA-B*0702 trans-
genic mice at 7 days (acute response) or up to 30 days (memory
response) post-intraperitoneal (intraperitoneal) infection with
1  107 pfu of VACV-WR as described previously (18). After
harvest, cells were stimulated for 2 h with RMA HLA-B*0702
cells infected with VACV-WR and incubated for 3 h in the
presence of 5 g/ml BFA. Later, cells were incubated with
FITC-conjugated anti-CD8 mAb (ProImmune, Oxford, UK)
for 30 min at 4 °C, fixed with Intrastain kit reagent A (Dako-
Cytomation, Glostrup, Denmark), and incubated with phyco-
erythrin-conjugated anti-IFN- mAb (Pharmingen) in the
presence of Intrastain kit permeabilizing reagent B for 30min at
4 °C. Results were acquired on a FACSCanto flow cytometer
(BD Biosciences) and analyzed using CellQuest Pro 2.0 soft-
ware (BD Biosciences).
T Cell Lines, Cytotoxicity Assays, and ICS—The TAP-inde-
pendent polyclonal VACV-polyspecific CD8 T cell line was
generated by immunizing mice intraperitoneally with 1  107
pfu of VACV-WR. Splenocytes from immunized mice were re-
stimulated weekly in vitro with mitomycin C-treated VACV-
infected RMAor RMA-SHLA-B*0702 cells as antigen-present-
ing cells. Also, uninfected mitomycin C-treated spleen cells of
allogeneic BALB/c (H-2d haplotype), C3H (H-2k haplotype),
and SJL (H-2s haplotype) mice were alternately used as feeder
cells. This allogeneic system prevents cross-presentation of
TAP-dependent HLA-B*0702-restricted peptides in the cell
culture. The CD8 T cell line was re-stimulated with VACV-
infected RMA-S HLA-B*0702 cells and was cultured in -min-
imal essential medium supplemented with 10% FBS and 1%
-mercaptoethanol and was used after five re-stimulations as
effector cells in standard 4-h cytolytic assays (18) or ICS stain-
ing similarly to ex vivo ICS.
Polyclonal SIINFEKL or VACV peptide-monospecific CTLs
were generated by immunizingmice intraperitoneally with 1
107 pfu of VACV-OVA(257–264) encoding the miniprotein
MSIINFEKL or VACV-WR as described previously (15, 19),
respectively. Splenocytes from immunized mice were restimu-
lated in vitrowithmitomycin C-treated spleen cells pulsedwith
106 M of the respective peptide and cultured in -minimal
essential medium supplemented with 10% FBS, 1  107 M
peptide, and 1% -mercaptoethanol. Recombinant human
interleukin-2 was generously provided by Hoffmann-La Roche
for the long term propagation of all CD8 T cell lines. ICS
assays to detect the recognition of infected cells by polyclonal
CD8 T cell lines were performed as described previously (17).
CD8 T cell lines were stimulated for 4 h with RMA HLA-
B*0702 target cells that had been infected with VACV or
Metalloproteases in Vaccinia Antigen Presentation
MARCH 23, 2012 • VOLUME 287 • NUMBER 13 JOURNAL OF BIOLOGICAL CHEMISTRY 9991
VACV-OVA(257–264) overnight and in the presence of 5
g/ml BFA.When protease inhibitors were used, all drugswere
added 15 min before the virus and kept at a 5-fold higher con-
centration during the 1-h adsorption period than that used
throughout the infection. After the virus inoculums were
washed, the inhibitors were kept at the concentrations indi-
cated for the individual experiments. The inhibitors were not
toxic at the indicated concentrations because they did not affect
antigen presentation of either the J6R(303–311) orD1RL((807–
817)) epitopes (see below) or the VACV infection when the
Omnitope antiserum with specificity for VACV proteins from
purified virions was used (ViroStat Inc., Portland,ME) (supple-
mental Table 1). ICS with polyclonal CD8 T cell lines was
performed similarly to ex vivo ICS. The percentage of specific
inhibition obtained by the addition of the inhibitors was calcu-
lated as shown in Equation 1,
% specific inhibition  100 
ICS VACV  inhibitor  (ICS without infection)
(ICS VACV  ICS without infection)
	 100
(Eq. 1)
Statistical Analysis—To analyze statistical significance, an
unpaired Student t test was used. p values  0.01 were consid-
ered to be significant.
RESULTS
Identification of Two VACV-derived TAP-independent HLA-
B*0702 Epitopes—Spleen cells from HLA-B*0702 transgenic
micewere primedwithVACVand re-stimulatedwith theTAP-
negative RMA-S cell line transfected with HLA-B*0702 to spe-
cifically recognize VACV-infected target cells. We observed
45% specific lysis versus 1% without virus in a standard 51Cr-
release assay. By intracellular cytokine staining (ICS) assays, we
found that 32% of IFN- secreting cells had a specific response
versus 1% without virus. Later, this CD8 cell line was used to
identify TAP-independent epitopes with target cells previously
pulsed with the VACV synthetic peptides previously reported
as HLA-B*0702 epitopes identified from either HLA-B*0702
transgenic mice (A34R(82–90), D1R(808–817), and J2R(116–
124)) (20) or human vaccines (AC1L(97–106), D1R(686–694),
F4L(6–14), and J6R(303–311)) (21, 22). In addition, 14HLA-B7
potential ligands from a VACV proteome-based in silico pre-
diction of high binding were also included in the study to iden-
tify new epitopes (supplemental Table 2). In a preliminary 51Cr-
release assay, only two synthetic peptides, D1R(808–817) and
J6R(303–311), were recognized by the TAP-independent CTL
cell line (Fig. 1A, arrows). Additional ICS experiments with all
synthetic peptides confirmed that only the D1R(808–817) and
J6R(303–311) peptides specifically stimulated the production
of IFN- in the CD8 T cells specific for VACV ligands (Fig.
1B). Fig. 2 shows that D1R(808–817) peptide was recognized
10-fold less efficiently in TAP-deficient cells versus TAP-suffi-
cient cells. Both viral ligands were conserved among the
Orthopoxviridae family, including cowpox virus (NCBI data
base (/blast.ncbi.nlm.nih.gov). In summary, these results indi-
cate that two conserved TAP-independent HLA-B7 epitopes
were present in the TAP-deficient VACV-infected cells.
Partial Interspecies Overlap in the CD8 Repertoire against
HLA-B*0702 Viral Epitopes—Previously, the D1R(808–817)
viral epitope was immunogenic in the HLA transgenic mouse
model (20), whereas the J6R(303–311) peptide was recognized
by peripheral blood mononuclear cells of an HLA-B7 donor
immunized with VACV (21). No interspecies overlap in the
CD8 repertoire against these two VACV epitopes or the other
five HLA-B*0702 epitopes has been reported (20–22). Because
the HLA-B*0702 transgenic mice used in this study (14) have a
different origin from those used the previous study (20), the
VACV-specific CD8 acute and memory responses in our
HLA-B7 transgenic model was evaluated using ex vivo ICS
assays. A strong acute response (6.1  0.4% of IFN--secreting
cells) specific for the D1R(808–817) synthetic peptide was
detected (Fig. 3). The A34R(82–90) and D1R(686–694) viral
peptides were also immunogenic, with 3.0 0.7 and 1.2 0.4%
CD8 IFN- cells, respectively. Additionally, a small fraction
of VACV-specific CD8 T lymphocytes recognized the
J6R(303–311) peptide (0.3  0.05% of IFN- cells, Fig. 3).
When the VACV memory response was analyzed (Fig. 3, filled
bars), an epitope hierarchy similar to the acute response was
found, except that the percentage of IFN- secreting cells was
slightly higher with the J6R(303–311) peptide (0.7 0.2%) than
with theD1R(686–694) epitope (0.5 0.1%).None of the other
17 VACV peptides tested (for list see Fig. 1 and supplemental
Table 1) stimulated the production of IFN- in the VACV-
specific CD8 T cell acute or memory response (data not
shown). Thus, two epitopes from both previously described
transgenic mouse models (D1R(808–817) and A34R(82–90))
and human donors (D1R(686–694) and J6R(303–311)) are
responsible for this specific CD8 response against VACV. The
same ex vivo epitope hierarchy was also found using a TAP-de-
pendent polyclonal VACV-polyspecific CD8 T cell line gen-
erated by re-stimulation in vitro with mitomycin C-treated
VACV-infected RMA (TAP) HLA-B*0702 cells as antigen-
presenting cells (data not shown). By contrast, in the previous
study with the HLA transgenic model, the epitope hierarchy
was A34R(82–90)  J2R(116–142)  D1R(808–817) (20).
These results show both the quantitative and the qualitative
differences between the two HLA-B*0702 transgenic mouse
models available, although only the CD8 response of the
HLA-B7 model used in our study showed partial overlap in
CD8 repertoire with the study of human vaccines (21). In
addition, these data show that half of the HLA-B7-restricted
viral epitopes detected in a normal TAP-dependent T cell
response could also be presented in a TAP-independent man-
ner in the HLA-B7 transgenic model.
Endogenous Processing of TAP-independent HLA-B*0702
Epitopes—To study all antigen-processing pathways involved
in the endogenous generation of the D1R(808–817) and
J6R(303–311) viral epitopes, polyclonal CD8 T cell lines
monospecific for the two TAP-independent HLA-B7 viral
epitopes were generated. Later, we investigated the presenta-
tion of these epitopes to respective specific CTLs in the pres-
ence of diverse protease inhibitors inVACV-infectedTAP-pro-
ficient cells. To test whether these HLA-B7-restricted epitopes
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require endogenous processing, we analyzed their presentation
in the presence of BFA. This drug blocks class I export beyond
the cis-Golgi compartment (23, 24), preventing the surface
expression of newly assembled class I-peptide complexes of
endogenous origin (Table 1 summarizes the specificity of all
inhibitors used in this study).We observed complete inhibition
of specific secretion of IFN- in the two specific CD8 T cell
lines by the addition of BFA during infection (Fig. 4), demon-
strating that these epitopes were indeed generated from pro-
teins endogenously processed in VACV-infected cells.
Proteasome Inhibitor Differentially Affects the Antigen Pres-
entation of TAP-independentHLA-B*0702Viral Ligands—Lac-
tacystin (LC), a bacterialmetabolite (Table 1) (25–27), was used
to study the role of the proteasome in the presentation of these
epitopes. LC partially blocks (45  15%) the specific recogni-
tion of target cells infected with VACV by J6R(303–311)-spe-
cific CD8 T cells (Fig. 4). By contrast, in the same experiment,
this drug had no effect on the presentation of the D1R(808–
817) epitope (3  12%) (Fig. 4). We observed complete inhibi-
tion of infected cell recognition by another VACV-specific
FIGURE 1. Recognition of HLA-B7-restricted synthetic peptides by a VACV-specific TAP-independent CD8 T cell line. RMA-HLA-B*0702 target cells
pre-pulsed with 105 M of the indicated VACV-synthetic peptides were tested in a standard cytolytic assay (A) or by ICS for CD8 T cell activation (B) with
VACV-specific CD8 T cells. The VACV-specific CD8 T cells were obtained from HLA-B*0702-transgenic mice immunized with VACV up to 30 days prior and
restimulated in vitro with the TAP-negative RMA-S cell line transfected with HLA-B*0702. Arrows in A indicate the synthetic peptides detected with 2-fold higher
specific lysis than the negative control (no peptide) in three E/T ratios. The data are the mean of four independent experiments  S.D. (B). Significant p value,
***, p  0.001.
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TAP CD8 T cell line with LC treatment (96  4%),3 indicat-
ing that LC-mediated inhibition of proteasome activity is not
absolutely required for antigen processing of the D1R(808–
817) epitope. This further suggests that the proteasome par-
tially contributes to the generation of the J6R(303–311) peptide
in infected cells.
AMetallopeptidase Inhibitor Specifically Blocks the Recogni-
tion of HLA-B*0702 Epitopes—To characterize proteases dis-
tinct from proteasomes that may contribute to the processing
of HLA-B*0702-restricted ligands, experiments with several
specific protease inhibitors were performed. Leupeptin (28),
pepstatin (28, 29), 1,10-phenanthroline (PHE) (29, 30), and E64
(31) inhibitors were initially tested because they are specific for
different protease families (Table 1) and cover a wide range of
protease classes. Puromycin (32) has also previously been sug-
gested to generate pathogen-derived peptides; thus, the possi-
ble role of this enzyme in endogenous presentation of TAP-
independent viral epitopes was studied using a specific
inhibitor (Table 1). Four of five inhibitors had no effect on the
specific recognition of target cells infected with VACVwith the
two specific CD8T cell lines tested (Fig. 5). Thus, the enzymes
inhibited by these drugs are not formally involved in the gener-
ation of TAP-independent ligands.
In contrast, PHE inhibited the recognition of infected cells by
J6R(303–311) (42  12%)- and D1R(808–817) (72  20%)-
specific CD8 T cells (Fig. 5). We wanted to exclude the possi-
bility that the inhibitory effect of PHE was due to toxic effects
on target cells or on VACV replication rather than to a specific
block of the respective proteases. To this end, experiments sim-
ilar to those shown in Fig. 5 were performed in parallel using
VACV-OVA(257–264)-infected target cells. These infected
cells were efficiently recognized by the SIINFEKL-specific
CD8 T cell line. and no inhibition was detected (10  4%, see
Fig. 5). These data indicate that inhibition of specific recogni-
tion in both CD8 T cell lines by addition of PHE is formally
due to specific blockage of the specific proteases not to a block
in VACV replication (see also supplemental Table 1). In sum-
mary, these results indicate that either a metallopeptidase or
different metalloproteases are involved in the generation of
these two HLA-B*0702 epitopes.
Metallocarboxyprotease andMetalloaminoproteases but Not
ERAP Are Differentially Involved in the Generation of TAP-in-
dependent HLA-B*0702 Epitopes—A variety of functional met-
allopeptidases are located in the cytosol or in other compart-
ments related to theMHC class I presentation pathway, such as
the ER and the trans-Golgi network (reviewed in Ref. 33). Any
of these enzymes may play a role in the endogenous pathway of
antigen processing. These enzymes can be grouped into amino-
peptidases, endopeptidases, carboxypeptidases, and carboxydi-
peptidases, among others, based on their respective cleavage
mechanism (reviewed in Ref. 34). Some of these groups can be
distinguished by the use of different specific inhibitors (sum-
marized in Table 1).
To more specifically identify the metallopeptidase group
involved in antigen processing of both D1R(808–817) and
J6R(303–311) viral peptides, VACV-infected target cells were
treated with specific subfamily inhibitors (Table 1). The
caspase-1-specific inhibitor benzyloxycarbonyl-VAD was also
included due to the sensitivity of this cysteine protease to PHE
(30). None of the inhibitory compounds used, except for leu-
cine thiol (LeuSH), prevented antigen presentation of VACV-
infected cells to the CD8 T cell line specific for the J6R(303–
311) viral peptide (Fig. 6, open bars).When similar experiments
were carried out with D1R(808–817)-specific CD8 T cells,
complete blockage of antigen recognition (84  11%) was also
detected in the presence of the LeuSH inhibitor. The inhibitory
effect of LeuSHwas specific to these two viral epitopes because
the recognition of VACV-OVA(257–264) cells by the SIIN-
FEKL-specific CD8 T cell line was not abrogated in the pres-
ence of this compound (12  10%, see Fig. 6). Thus, these data
implicate ERAP or other metallo-aminopeptidases in the gen-
eration of the two VACV epitopes studied.3 E. Lorente and D. López, manuscript in preparation.
FIGURE 2. Recognition of TAP and TAP cell lines by VACV-specific CD8
T lymphocytes. Recognition by ICS for CD8 T cell activation of titration
curves of D1R(808 – 817) synthetic peptide in HLA-B*0702 TAP (RMA, circles)
and TAP (RMA-S, squares) cells. The VACV-specific CD8 T cells were
obtained as Fig. 1. Results are the mean of three experiments.
FIGURE 3. Immunogenicity of VACV-derived HLA-B*0702-restricted pep-
tides in HLA-B*0702 transgenic mice. RMA-HLA-B*0702 target cells pre-
pulsed with the indicated VACV synthetic peptides in Fig. 1 were analyzed by
ICS for CD8 T cell activation with VACV-specific splenocytes obtained from
HLA-B*0702 transgenic mice immunized 7 days (acute response, open bars) or
up to 30 days (memory, closed bars) post-infection. The results are calculated
as the mean of three or four independent experiments  S.D. Significant p
values are as follows: *, p  0.05; **, p  0.01; ***, p  0.001.
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In addition, as shown in Fig. 6, a partial but specific blockage
of the endogenous processing of the D1R(808–817) epitope by
either themetalloaminoprotease inhibitor bestatin (BES) or the
metallocarboxypeptidase inhibitor benzyl succinyl acid (BEN)
was detected (44 15%of specific inhibitionwithBES and 42
16% with BEN). Thus, both metalloaminoprotease and metal-
TABLE 1
Specificity and activity of the inhibitors used in this study
Inhibitor Abbreviation Specificity Reference Concentration
% inhibition of
degradationa
Brefeldin A BFA Vesicle transport 23, 24 5 g/ml ND
Lactacystin LC Proteasome 25, 26 10 M ND
Leupeptin LEU Trypsin-like proteases and cysteine proteases 28 100 M 38  18
Pepstatin PEP Aspartic proteases 28, 29 100 M 50  5
1,10-Phenanthroline PHE Metalloproteases and caspase-1 29, 30 50 M ND
E64 E64 Cysteine proteases C1 31 100 M ND
Puromycin PUR Dipeptidyl-peptidase II and PSA 61 0.5 g/ml ND
Captopril CAP ACE and ACE-like proteases 29 100 M 25  2
Benzyl succinyl acid BEN Metallo-carboxypeptidases A and B 29 100 M 10  8
Bestatin BES Most of metallo-aminopeptidases 29 50 M ND
Phosphoramidon PHO All bacterial metallo-endopeptidases but few
of mammalian origin
29, 62 100 M 15  4
Leucine thiol LeuSH Metallo-aminopeptidases including ERAP 57 30 M ND
Benzyloxycarbonyl-VAD-fluoromethyl
ketone
Z-VAD-fmk Caspases 63 100 M NDb
a Activity of these inhibitors was measured as their ability to prevent proteolytic degradation in cellular extracts as in Ref. 15. The amount of protein still present after incu-
bation in the case of the degraded control sample was considered 0% inhibition of degradation, and the nondegraded sample was taken as 100% inhibition. Data are means
of two independent experiments. Negative values indicate that there was enhanced degradation in the presence of the compound. ND indicates not done.
b The compound was found to block apoptosis (data not shown).
FIGURE 4. Effect of BFA and a proteasome inhibitor on the recognition of the J6R(303–311) or the D1R(808 – 817) viral epitopes. RMA-HLA-B*0702 target
cells infected for 16 h with VACV at a multiplicity of infection of 40 plaque-forming units/cell were treated with BFA or LC. An ICS assay was used to test for
recognition by the J6R(303–311)- (open bars) or D1R(808 – 817)-specific (closed bars) CD8 T cell lines. The data are expressed as percentage of inhibition  S.D.
as determined by ICS in the presence of the indicated inhibitors and are means of three to four independent experiments. Significant p value, **, p  0.01.
Representative ICS assays with J6R(303–311)- and D1R(808 – 817)-specific CD8 T cell lines were depicted in the middle and bottom panels, respectively. The
percentages of IFN--expressing CD8 T cells are indicated in each dot plot.
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locarboxyproteases are involved in the antigen processing of
the D1R(808–817) epitope.
J6R(303–311) Epitope May Be Processed in Parallel Either by
Proteasomes or byMetallopeptidases Independently—The inhi-
bition of antigen recognition by either LC (Fig. 4) or PHE (Fig.
5) indicates that both proteasomes and metalloproteases are
involved in the antigen presentation of the J6R(303–311)
epitope. The identical partial inhibition of VACV-infected cell
recognition detectedwith both reagents (45 15 and 42 12%
in the presence of LC or PHE, respectively) is compatible with
two possible explanations. First, this epitope could be pro-
cessed by proteasomes and metallopeptidases in a sequential
pathway, and other uncharacterized proteases may be respon-
sible for the other half of the antigen. Alternatively, these
epitopes could be processed in parallel by proteasomes or by
metallopeptidases independently, meaning that these two anti-
gen-processing pathways would need to be inhibited at the
same time to fully abrogate the specific recognition by J6R(303–
311)-specific CD8Tcells. To test these hypotheses, the effects
of the combination of both inhibitors on antigen presentation
in vaccinia-infected cells were analyzed. A total block of pres-
entation (97  3%) was observed in target cells treated simul-
taneously with LC and PHE (Fig. 7). The inhibitory effect of LC
and PHE was specific to these two viral epitopes because the
recognition of VACV-OVA(257–264) cells by the SIINFEKL-
specific CD8 T cell line was not abrogated in the presence of
these drugs (5  10%, see Fig. 7). These results demonstrate
that proteasomes and metallopeptidases are involved in two
different antigen-processing pathways that contribute inde-
pendently to the presentation of the J6R(303–311) epitope.
Sequential Cleavage by Amino- and Carboxy-metallopepti-
dases Is Involved in Antigen Processing of the D1R(808–817)
Epitope—Like the J6R(303–311) epitope, the partial block of
D1R(808–817) epitope recognition detected in the presence of
BES or BEN (44 15 and 42 16%, respectively) is compatible
with either sequential cleavage by amino- and carboxy-metal-
lopeptidases or the activity of these enzymes in two different
antigen-processing pathways to produce the D1R(808–817)
epitope. The incubation of VACV-infected target cells with a
mixture of both reagents produced a partial inhibition of anti-
gen presentation (46  4%, see Fig. 7), similar to two single
inhibitors (Fig. 6). The inhibitory effect of the two metallopep-
tidase inhibitors was specific to the two viral epitopes because
the recognition of VACV-OVA(257–264) cells by the SIIN-
FEKL-specific CD8 T cell line was not abrogated in the pres-
ence of BEN plus BES (7  9%, see Fig. 7). Thus, both metal-
loaminoprotease and metallocarboxyproteases contribute to
D1R(808–817) epitope cleavage in the same antigen-process-
ing pathway. In addition, another uncharacterized protease is
responsible for the BEN plus BES-resistant antigen processing
detected with D1R(808–817)-specific CD8 T cells.
Diversity of Proteases Involved in Antigen Recognition of Vac-
cinia HLA-B7-restricted Epitopes—Table 2 summarizes the
various inhibition patterns for antigen recognition of the
J6R(303–311) and D1R(808–817) epitopes obtained with
the drugs used in this study (Table 1). The inhibition observed
with BFA indicates that both viral peptides were endogenously
processed. The block with LC and PHE indicates that both pro-
teasomes andmetalloproteases are used in the processing of the
J6R(303–311) epitope. Also, the LeuSH inhibitor impaired anti-
gen recognition of target cells by J6R(303–311)-specific CD8
T cells. The second epitope, D1R(808–817), shows a different
inhibition pattern. LC had no effect on the presentation of this
epitope, and thus, LC-mediated inhibition of proteasome activ-
ity is not absolutely required for antigen processing of the
D1R(808–817) epitope. By contrast, PHE, BEN, BES, and
LeuSH significantly decreased antigen presentation of the
D1R(808–817) epitope; thus, a variety of metalloproteases are
involved in the generation of this TAP-independent epitope.
DISCUSSION
This study was undertaken to identify TAP-independent
HLA-B*0702 epitopes from the vaccinia virus and to study their
antigen presentation pathways. First, our results indicate that
two of four epitopes detected in the standard antiviral response
FIGURE 5. Recognition of VACV-infected cells by J6R(303–311)- or
D1R(808 – 817)-specific CD8 T cells in the presence of general protease
inhibitors. Cells infected as described in Fig. 4 were treated with leupeptin
(LEU) (trypsin-like and cysteine protease inhibitor), pepstatin (PEP) (aspartic
protease inhibitor), PHE (metallopeptidase inhibitor), E64 (cysteine protease
C1 inhibitor), or puromycin (PUR) (dipeptidyl-peptidase II and PSA), as indi-
cated, before the ICS assay. J6R(303–311)- (open bars), D1R(808 – 817)- (closed
bars), or SIINFEKL-specific (hatched bars) CD8 T cell lines were used. The
percentage of specific inhibition was calculated as in Fig. 4. The data are
means  S.D. of three or four independent experiments. Significant p value,
**, p  0.01. Representative ICS assays with J6R(303–311)- and D1R(808 –
817)-specific CD8 T cell lines were depicted in the medium and bottom
panels, respectively. The percentages of IFN--expressing CD8 T cells are
indicated in each dot plot.
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from the H-2 class I double knock-out HLA-B*0702 transgenic
mice (14) are presented by TAP-independent pathways as fol-
lows: the immunodominant D1R(808–817) epitope and the
J6R(303–311) vaccinia peptide detected in human donors.
Thus, TAP-independent HLA-B*0702 antigen presentation is
sufficient to control vaccinia virus infection in the absence of a
functional TAP complex. If these data are typical for all HLA
class I molecules, this may help explain why individuals with
unusable TAP complexes do not seem particularly susceptible
to viral infections and may appear asymptomatic for much of
their lives (reviewed in Ref. 5).
The sources of the two TAP-independent epitopes identified
were the vaccinia J6R and D1R proteins. The J6R protein is a
component of the viral RNA polymerase complex (35). The
D1R protein is the large subunit of the viral mRNA capping
enzyme (36) and is needed for early transcription termination
(37). Presumably, the RNA polymerase carries the capping
enzyme along as it transverses the template as a transcription
elongation complex (38). Presentation of cytosolic proteins in
cells lacking TAP has been previously reported (39, 40). This
presentation of peptides could occur by passive diffusion (41),
hydrophobic peptides with the ability to traverse membranes
(42), or unidentified transport. Thus, either these VACV pro-
teins or their respective ligands could be accessible to HLA-
containing compartments with resident proteases for their
TAP-independent HLA class I antigen processing and
presentation.
Several proteases have been implicated in the processing of
endogenously synthesized antigens independent of the classical
proteasome pathway as follows: signal peptidase (43, 44); furin
(45, 46); tripeptidyl peptidase II (47–49); lysosomal chloro-
quine-sensitive enzymes (50, 51); and caspases (52, 53). In this
study, diverse proteolytic activities are required to generate the
twoHLA-B7-restricted epitopes studied. Our results using var-
ious protease inhibitors (summarized in Table 2) are consistent
with the models depicted in Fig. 8. The block with LC indicates
that the proteasome plays a role in the processing of the
FIGURE 6. Recognition of target cells infected in the presence of metalloproteinase subfamily inhibitors. Cells infected as described in Fig. 4 were treated
with captopril (CAP) (ACE-like metallopeptidase inhibitor), BEN (inhibits metallo-carboxypeptidases), BES (metallo-aminopeptidase inhibitor), phosphorami-
don (PHO) (bacterial metalloendopeptidase inhibitor), LeuSH (mainly ERAP and other metallo-aminopeptidase inhibitor), or benzyloxycarbonyl-VAD (zVAD)
(blocks caspases) as indicated, before the ICS assay. The figure is labeled as in Fig. 5. The percentage of specific inhibition was calculated as in Fig. 4. The data
are means  S.D. of three to four independent experiments. Significant p value, **, p  0.01. Representative ICS assays with D1R(808 – 817)-specific CD8 T cell
lines are depicted in the bottom panels. The percentages of IFN--expressing CD8 T cells are indicated in each dot plot. ACE, angiotensin converting enzyme.
FIGURE 7. Effect of combinations of inhibitors in the recognition of VACV-
infected cells. Cells infected as described in Fig. 4 were treated with the
combination of either LC and PHE or BEN and BES, as indicated, before the ICS
assay. The figure is labeled as in Fig. 5. The percentage of specific inhibition
was calculated as in Fig. 4. The data are means  S.D. of three or four inde-
pendent experiments. Significant p value, **, p  0.01. ACE, angiotensin con-
verting enzyme.
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J6R(303–311) epitope but not the D1R(808–817) viral ligand.
The presentation of both vaccinia peptides was dependent on
PHE-sensitive proteases, indicating that metalloprotease activ-
ity is required to process these epitopes. The LeuSH inhibitor
impaired antigen recognition of target cells by both D1R(808–
817) and J6R(303–311)-specific CD8T cells. Because the pan-
specificmetalloprotease inhibitor PHEand the inhibitor of gen-
eral aminoprotease activities BES did not block or had very little
effect on ERAP (54, 55), the inhibition of D1R(808–817)- or
J6R(303–311)-specific recognition requires both ERAP and
other similar metalloproteases. In addition, the partial but
selective impaired recognition of VACV-infected cells by
D1R(808–817)-specific T cells in the presence of BEN or BES,
whichwas not increasedwhen both drugs were added together,
implies that amino- (different from ERAP) and carboxy-metal-
lopeptidases contribute sequentially to D1R(808–817) antigen
processing. By contrast, the higher inhibition detected in the
presence of LC and PHE versus single inhibitors demonstrated
that the antigen processing of the J6R(303–311) epitope
requires proteasomes and metallopeptidases independently.
Last, the recognition of VACV-infected cells by J6R(303–
311)-specificCD8Tcellswas partially blocked byPHEbut not
by the inhibitors ofmetalloproteases used in this study. Because
phosphoramidon very efficiently inhibits bacterial metalloen-
dopeptidases but does not block multiple higher vertebrate
metallo-endoproteases, the most likely explanation for PHE-
specific inhibition of J6R(303–311) recognition is that some
mammalian metalloendopeptidases that are not blocked by
phosphoramidon are involved in the antigen processing of this
viral ligand. Similarly, therewas higher inhibition of the antigen
recognition of the D1R(808–817) epitope with PHE than with
the combination of BEN and BES, suggesting additional met-
allo-endoprotease activity. More than 100 different well char-
acterized higher vertebrate metalloendopeptidases are resis-
tant to this reagent (33), and drugs that collectively and
specifically block the endoproteolytic activity of this group of
enzymes have not been described. Therefore, positive identifi-
cation of the peptidase involved in the processing of these TAP-
independent vaccinia epitopes awaits further characterization.
In summary, the J6R(303–311) product appears to be pro-
cessed in parallel either by proteasomes or by metalloendopep-
tidases independently. Later, ERAP trims the final epitope. The
processing of the D1R(808–817) epitope is more complex,
involving a branched pathway in which metallo-endoproteases
and a sequential cleavage of both metalloaminoprotease and
metallocarboxyproteases are required to generate this epitope.
As preceding epitope J6R(303–311), the trimming by ERAP
generates the final D1R(808–817) epitope.
Metallopeptidases are among the hydrolases in which the
nucleophilic attack on a peptide bond is mediated by a water
molecule previously activated by a divalent metal cation (33).
These proteases are allocated to 14 clans and subdivided into 62
families (MEROPS data base) (56). Based on their respective
cleavage mechanism, these enzymes can be grouped into
aminopeptidases, endopeptidases, carboxypeptidases, and car-
boxy-dipeptidases, among others (reviewed in Ref. 33). The ER
resident amino-metallopeptidase ERAP plays an essential role
in the trimming of different MHC class I ligands (3, 54, 57). In
our study, we found that an ERAP-specific inhibitor blocks
antigen presentation of both TAP-independent vaccinia
ligands studied. Other amino-metallopeptidases also travel by
the secretory pathway to their destination organelle or to the
extracellular medium (33) and could be responsible for the
BES-mediated inhibition observed in the antigen processing of
the D1R(808–817) epitope. Also, carboxy-metallopeptidases
abound in the secretory pathway and in vesicular compart-
ments accessible to HLA class I molecules (33). Currently, no
individual carboxypeptidases have been implicated in antigen
processing in the vesicular pathway, but indirect evidence has
been reported in two cases. First, the proteolytic action of furin
in the secretory pathway is required to generate the antigenic
CMV pp89 epitope located in the sHBe chimera (46). After this
cleavage, nine C-terminal residues must be trimmed from the
precursor peptide to generate the optimal 9pp89 epitope, and
thus carboxypeptidasesmay be involved. Second, various signal
sequence-derived peptides generated by signal peptidase com-
plexes have C-terminally extended residues compared with the
optimal HLA-bound epitope isolated (58–60); thus, carboxy-
peptidases may be involved in antigen processing of these
TABLE 2
Summary of inhibition patterns
Epitope BFAa LC PHE BEN BES LeuSH LC  PHE BEN  BES
J6R( 303–311) b       
D1R(807–817)        
a For specificity of different inhibitors see Table 1.
b , , , and  indicate % inhibition 20, 40–60, 61–80, and 81% respectively. All  inhibitions show significant p values (p  0.01) versus controls without an
inhibitor.
FIGURE 8. Diversity of proteases and processing pathways involved in
J6R(303–311) or D1R(808 – 817) epitope presentation. The models show
the components involved in each of the proposed pathways for the J6R(303–
311) (upper panel) or D1R(808 – 817) (lower panel) epitopes. The role of pro-
teases is deduced from the sensitivity of respective CD8 T cells to the various
inhibitors (see Table 2).
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epitopes. This study directly implicates carboxy-metallopepti-
dases in the antigen processing of the vaccinia D1R(808–817)
epitope. Finally, unknown metalloendopeptidases are involved
in the processing of an HIV-1 epitope in a sequential TAP-de-
pendent pathway that also implicates cleavage by proteasomes
(15). In our study, proteasomes and uncharacterized met-
alloendopeptidases were found to be involved in J6R(303–311)
cleavage in two different antigen-processing pathways.
In conclusion, the results reported here highlight the diver-
sity of proteases involved in antigen recognition, and they
uncover the complexity of antigen-processing pathways.
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52. López, D., García-Calvo,M., Smith, G. L., andDel Val,M. (2010) Caspases
in virus-infected cells contribute to recognition by CD8 T lymphocytes.
J. Immunol. 184, 5193–5199
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